Characterization of the E138K resistance mutation in HIV-1 reverse transcriptase conferring susceptibility to etravirine in B and non-B HIV-1 subtypes

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 2, 2011, Pages 600-607

  Asahchop, Eugene L ^a,b   Oliveira, Maureen ^a   Wainberg, Mark A ^a   Brenner, Bluma G ^a   Toni, Thomas D'Aquin ^a   Tremblay, Cecile L ^b  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; ETRAVIRINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CONTROLLED STUDY; GENE IDENTIFICATION; GENE MUTATION; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR CLONING; MONONUCLEAR CELL; NONHUMAN; PHENOTYPE; PLASMID; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS; TISSUE CULTURE; VIRUS ISOLATION; VIRUS REPLICATION;

AMINO ACID SEQUENCE; ANTI-HIV AGENTS; CELL LINE; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; MUTATION; PYRIDAZINES; SEQUENCE ALIGNMENT;

EID: 78751693611     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01192-10     Document Type: Article

References (51)

1. Aghokeng, A. F., et al. 2009. Evaluation of transmitted HIV drug resistance among recently infected antenatal clinic attendees in four Central African countries. Antivir. Ther. 14:401-411.
2. Andries, K., et al. 2004. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 48:4680-4686.
3. Antinori, A., et al. 2002. Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure. AIDS Res. Hum. Retrovir. 18:835-838.
4. Azijn, H., et al. 2010. TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1. Antimicrob. Agents Chemother. 54:718-727.
5. Basavapathruni, A., C. M. Bailey, and K. S. Anderson. 2004. Defining a molecular mechanism of synergy between nucleoside and nonnucleoside AIDS drugs. J. Biol. Chem. 279:6221-6224.
6. Brenner, B., et al. 2003. A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. AIDS 17:F1-F5.
7. Brenner, B. G., et al. 2006. HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture. AIDS 20:F9-F13.
8. Brillant, J. E., K. K. Swallow, S. Cammack, N., and G. Heilek-Snyder. 2004. In vitro resistance development for a second-generation NNRTI: TMC125. Antivir. Ther. 9(Suppl. 1):S20.
9. Briz, V., et al. 2009. Raltegravir and etravirine are active against HIV type 1 group O. AIDS Res. Hum. Retroviruses. 25:225-227.
10. Collins, J. A., et al. 2004. Competitive fitness of nevirapine-resistant human immunodeficiency virus type 1 mutants. J. Virol. 78:603-611. (Pubitemid 38067582)
11. Coutsinos, D., et al. 2009. Template usage is responsible for the preferential acquisition of the K65R reverse transcriptase mutation in subtype C variants of human immunodeficiency virus type 1. J. Virol. 83:2029-2033.
12. Das, K., et al. 2004. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J. Med. Chem. 47:2550-2560.
13. Ferris, R. G., et al. 2005. Antiviral activity of GW678248, a novel benzophenone nonnucleoside reverse transcriptase inhibitor. Antimicrob. Agents Chemother. 49:4046-4051.
14. Gao, Q., et al. 1993. The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2′,3′-dideoxy-3′-thiacytidine. Antimicrob. Agents Chemother. 37:1390-1392.
15. Gatanaga, H., et al. 2010. Impact of human leukocyte antigen-B*51- restricted cytotoxic T-lymphocyte pressure on mutation patterns of nonnucleoside reverse transcriptase inhibitor resistance. AIDS 24:F15-F22.
16. Gotte, M., X. Li, and M. A. Wainberg. 1999. HIV-1 reverse transcription: a brief overview focused on structure-function relationships among molecules involved in initiation of the reaction. Arch. Biochem. Biophys. 365:199-210.
17. Guoping Su, Y. L., et al. 2007. In vitro selection and characterization of viruses resistant to R1206, a novel nonnucleoside reverse transcriptase inhibitor. Antivir. Ther. 12:S35.
18. Hemelaar, J., E. Gouws, P. D. Ghys, and S. Osmanov. 2006. Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS 20:W13-W23.
19. Hurt, C. B., et al. 2009. Transmitted antiretroviral drug resistance among acute and recent HIV infections in North Carolina from 1998 to 2007. Antivir. Ther. 14:673-678.
20. Javanbakht, H., et al. 2010. In vitro resistance development for RO-0335, a novel diphenylether nonnucleoside reverse transcriptase inhibitor. Antiviral Res. 86:212-219.
21. Kantor, R., et al. 2005. Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med. 2:e112.
22. Kekitiinwa, A., F. D. Coakley, E. Lie, and Y. Frank Granziano. 2010. Profiling etravirine resistance in Ugandan children with extended failure of a NNRTI-inclusive regimen as first-line ART, abstr. 891. CRIO, San Francisco, CA.
23. Kiertiburanakul, S., S. Wiboonchutikul, C. Sukasem, W. Chantratita, and S. Sungkanuparph. 2010. Using of nevirapine is associated with intermediate and reduced response to etravirine among HIV-infected patients who experienced virologic failure in a resource-limited setting. J. Clin. Virol. 47:330-334.
24. Lapadula, G., et al. 2008. Prevalence and risk factors for etravirine resistance among patients failing on non-nucleoside reverse transcriptase inhibitors. Antivir. Ther. 13:601-605.
25. Llibre, J. M., et al. 2008. Prevalence of etravirine-associated mutations in clinical samples with resistance to nevirapine and efavirenz. J. Antimicrob. Chemother. 62:909-913.
26. Loemba, H., et al. 2002. Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against nonnucleoside inhibitors of RT. Antimicrob. Agents Chemother. 46:2087-2094.
27. Madruga, J. V., et al. 2007. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 370:29-38.
28. Maiga, A. I., et al. Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naive patients infected with non-B HIV-1 subtypes. Antimicrob. Agents Chemother. 54:728-733.
29. Manosuthi, W., et al. 2010. Patients infected with HIV type 1 subtype CRF01-AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. AIDS Res. Hum. Retroviruses. 26:609-611.
30. Marcelin, A. G., et al. 2010. Mutations selected in patients displaying treatment failure under an etravirine-containing regimen. Antivir. Ther. 15(Suppl. 2):A64.
31. Marcelin, A. G., et al. Factors associated with virological response to etravirine in nonnucleoside reverse transcriptase inhibitor-experienced HIV-1-infected patients. Antimicrob. Agents Chemother. 54:72-77.
32. Mojgan Haddad, E. S., J. Benhamida, and E. Coakley. 2010. Improved genotypic algorith for predicting etravirine susceptibility: comprehensive list of mutations identified through correlation with matched phenotype, abstr. 574. CROI, San Francisco, CA.
33. Nadler, J. P., et al. 2007. Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis. AIDS 21:F1-F10.
34. Oliveira, M., B. G. Brenner, and M. A. Wainberg. 2009. Isolation of drugresistant mutant HIV variants using tissue culture drug selection. Methods Mol. Biol. 485:427-433.
35. Petrella, M., et al. 2004. Differential maintenance of the M184V substitution in the reverse transcriptase of human immunodeficiency virus type 1 by various nucleoside antiretroviral agents in tissue culture. Antimicrob. Agents Chemother. 48:4189-4194.
36. Poveda, E., et al. 2010. Etravirine resistance associated mutations in HIV-infected patients failing efavirenz or nevirapine in the Spanish antiretroviral resistance database. AIDS 24:469-471.
37. Poveda, E., et al. 2008. Phenotypic impact of resistance mutations on etravirine susceptibility in HIV patients with prior failure to nonnucleoside analogues. AIDS 22:2395-2398.
38. Ren, J., et al. 2008. Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors. J. Med. Chem. 51:5000-5008.
39. Riddler, S. A., et al. 2008. Class-sparing regimens for initial treatment of HIV-1 infection. N. Engl. J. Med. 358:2095-2106.
40. Salomon, H., et al. 1994. Comparison of cord blood and peripheral blood mononuclear cells as targets for viral isolation and drug sensitivity studies involving human immunodeficiency virus type 1. J. Clin. Microbiol. 32:2000-2002.
41. Shafer, R. W., et al. 2003. Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N. Engl. J. Med. 349:2304-2315.
42. Taiwo, B., et al. 2010. Suboptimal etravirine activity is common during failure of nevirapine-based combination antiretroviral therapy in a cohort infected with non-B subtype HIV-1. Curr. HIV Res. 8:194-198.
43. Tambuyzer, L., et al. 2009. Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors. Antivir. Ther. 14:103-109.
44. Tambuyzer, L., et al. 2010. Characterization of genotypic and phenotypic changes in HIV-1-infected patients with virologic failure on an etravirine-containing regimen in the DUET-1 and DUET-2 clinical studies. AIDS Res. Hum. Retroviruses. 26:1197-1205.
45. Udier-Blagovic, M., J. Tirado-Rives, and W. L. Jorgensen. 2003. Validation of a model for the complex of HIV-1 reverse transcriptase with nonnucleoside inhibitor TMC125. J. Am. Chem. Soc. 125:6016-6017.
46. Van Houtte, M., et al. 2009. A comparison of HIV-1 drug susceptibility as provided by conventional phenotyping and by a phenotype prediction tool based on viral genotype. J. Med. Virol. 81:1702-1709.
47. Vingerhoets, J., et al. 2005. TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments. J. Virol. 79:12773-12782.
48. Vingerhoets, J., et al. 2010. Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled phase III clinical studies. AIDS 24:503-514.
49. Vingerhoets, J., T. L. Azijn, H. Nijs, and S. G. Picchio. 2010. Effect of Mutations at position E138 of HIV-1 reverse transcriptase on phenotypic susceptibility and virological response to etravirine. Antivir. Ther. 15(Suppl. 2):A125.
50. Xu, H., et al. 2009. Human immunodeficiency virus type 1 recombinant reverse transcriptase enzymes containing the G190A and Y181C resistance mutations remain sensitive to etravirine. Antimicrob. Agents Chemother. 53:4667-4672.
51. Xu, H. T., et al. 2010. The M230L nonnucleoside reverse transcriptase inhibitor resistance mutation in HIV-1 reverse transcriptase impairs enzymatic function and viral replicative capacity. Antimicrob. Agents Chemother. 54:2401-2408.